BEVICRA 400MG INJ is a prescription medication used to treat various types of cancer, including:
- Metastatic colorectal cancer (mCRC)
- Non-small cell lung cancer (NSCLC)
- Renal cell carcinoma (RCC)
- Breast cancer
- Brain cancer
- Ovarian cancer
It is a monoclonal antibody that works by blocking the action of vascular endothelial growth factor (VEGF), a protein that helps form new blood vessels that feed tumors.
Composition:
Each vial of BEVICRA 400MG INJ contains 400mg of bevacizumab.
Mechanism of Action:
Bevacizumab works by:
- Binding to VEGF and preventing it from binding to its receptors on the surface of endothelial cells
- Inhibiting the growth of new blood vessels that feed the tumor
- Reducing the amount of oxygen and nutrients that reach the tumor, leading to its shrinkage and eventual death
Uses:
BEVICRA 400MG INJ is used to treat various types of cancer, including:
- Metastatic colorectal cancer (mCRC) in combination with chemotherapy
- Non-small cell lung cancer (NSCLC) in combination with chemotherapy
- Renal cell carcinoma (RCC) in combination with interferon alfa
- Breast cancer in combination with chemotherapy or hormone therapy
- Brain cancer in combination with chemotherapy
- Ovarian cancer in combination with chemotherapy
Dosage:
The recommended dosage of BEVICRA 400MG INJ is:
- 400mg administered as an intravenous infusion over 30-60 minutes every 2-3 weeks
Side Effects:
Common side effects of BEVICRA 400MG INJ include:
- Hypertension (high blood pressure)
- Proteinuria (excess protein in the urine)
- Hemorrhage (bleeding)
- Nausea and vomiting
- Fatigue
- Headache
- Rash
- Diarrhea
Recommendation:
BEVICRA 400MG INJ is recommended for patients who have not received prior therapy for their specific type of cancer. Patients should also be advised to monitor their blood pressure and urine output regularly during treatment.
Important Note:
Patients should not take BEVICRA 400MG INJ if they have a history of severe allergic reactions, bleeding disorders, or eye problems. Patients should also inform their healthcare provider if they have any underlying medical conditions, such as high blood pressure, kidney problems, or seizure disorders, before taking BEVICRA 400MG INJ.
Some common brands of bevacizumab include:
- Avastin (Roche)
- Mvasi (Amgen)
- Bevacizumab-awwb (Amgen)
- Bevacizumab-bvzr (Biocon/Biocon Biologics)
Please note that BEVICRA 400MG INJ is not available in all markets and may be approved for different indications and dosages in different regions.
Reviews
There are no reviews yet.